Lord’s Marks Collaboration with CMET to Develop World’s First AI-Based Breast Cancer Detection Device

Lord’s Mark Industries Limited has entered into a Technology Transfer Agreement with the Centre for Materials for Electronic Technology (CMET) to manufacture an AI-powered, radiation-free Breast Screening Wearable Device for early detection of breast cancer.

India ranks third globally in new breast cancer incidence after China and the US, with the disease accounting for over 26% of all female cancers in the country. The global breast cancer market was valued at USD 4,882.14 million in 2024 and is projected to reach USD 12,880.85 million by 2035 at a CAGR of 9.22% (MRFR). Grand View Research highlights diagnostics as the largest segment driven by early detection demand, while Future Market Insights estimates the screening and diagnostics market at USD 5.05–5.86 billion in 2025, expected to reach USD 10.5–11.36 billion by 2033–2035.

The wearable integrates thermal sensors with AI-driven temperature mapping to identify early-stage abnormalities in a non-invasive, radiation-free manner. The partnership combines CMET’s R&D expertise with Lord’s Mark’s manufacturing capabilities and distribution network, supporting indigenous med-tech innovation.

Key Features & Advantages

• Convenient & Infrastructure-Light: Usable in various settings with minimal setup across hospitals, clinics, community centers, and homes.
• Non-Radiative & Painless: Eliminates radiation exposure and discomfort, supporting screening compliance.
• Advanced Thermal Sensors: High-precision temperature mapping supported by AI-driven analytics for real-time insights
• Privacy-First Design: Discreetly wearable under clothing, ensuring dignity and user comfort.
• Early Abnormality Detection: Identifies early-stage thermal irregularities to support timely medical evaluation
• Portable & Scalable: Lightweight, mobile solution enabling deployment across urban and underserved regions alike.

The device represents an alternative approach to traditional mammography by eliminating radiation exposure and discomfort, expanding access beyond hospital settings, and delivering AI-driven detection insights.

With this initiative, Lord’s Mark states its commitment to developing accessible, AI-led healthcare solutions—aiming to contribute to preventive diagnostics in India.

Sachidanand Upadhyay, Managing Director, Lord’s Mark Industries Limited, commenting on the partnership with CMET, said: “This collaboration marks a defining step in our journey to build globally competitive, indigenous healthcare technologies. By integrating CMET’s scientific expertise with Lord’s Mark’s manufacturing strength, we are enabling a new paradigm in preventive diagnostics—non-invasive, AI-driven, and truly accessible. Our vision is to reduce barriers to early detection and empower women across India with safer, smarter screening solutions. This is not just a product initiative; it is a commitment to scalable, impact-led healthcare innovation.”

With this initiative, Lord’s Mark reinforces its commitment to technology-led healthcare manufacturing focused on intelligent, inclusive, and impact-driven solutions that can make early detection safer, simpler, and more accessible nationwide. The company states that it plans to commercialise this product for mass breast cancer screening across India and internationally, and that it aims to make the technology available through its global network.

Lord’s Mark Industries Limited aims to make screening more affordable so that women in India and abroad may voluntarily choose to get tested. This may help increase awareness and support early detection. The product is expected to be available for commercial use globally by the end of this year.

For more information, visit - http://lordsmark.com

Note to the Reader: This article is part of Mint's promotional consumer connect initiative and is independently created by the brand. Mint assumes no editorial responsibility for the content.